The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
about
Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies.Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in contextPembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.Mitomycin C treatment induces resistance and enhanced migration via phosphorylated Akt in aggressive lung cancer cells.Targeted Expression of miR-7 Operated by TTF-1 Promoter Inhibited the Growth of Human Lung Cancer through the NDUFA4 Pathway.Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.Selumetinib for the treatment of non-small cell lung cancer.JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer.Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design.Spotlight on landmark oncology trials: the latest evidence and novel trial designs.Precision medicine in lung cancer: the battle continues.Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing.MEK inhibitors under development for treatment of non-small-cell lung cancer.Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials.Implications of KRAS mutations in acquired resistance to treatment in NSCLC.Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies.Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements.The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience.Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer
P2860
Q37583786-0A4F55D2-83D6-4B3E-8910-B54CAC7B06F5Q37669352-54E5FD9B-BB97-4B09-9066-FCB426E7ABE6Q37688658-B3750D0A-7B36-4A19-A80D-17857DB25FF6Q37694878-584C1849-6A36-474C-A2BD-CCBECE9586C7Q37718177-E87AE8EB-8B93-4490-B658-CE87E6974F10Q37743107-06F1F6A8-F813-4CDB-B90A-FE13095E11A3Q38663069-70829898-1E96-4503-9FA6-D24972DB3A1AQ38669181-C71FE7CD-8722-4CA4-B39E-09F336F0FA15Q42332672-3371DB6B-7B42-4E08-9F5A-25336A09F536Q42343618-36AA910C-99CB-4E41-BFD5-8E098A51CD40Q42344274-461685B0-74A8-4D3A-93BF-F64A7602DAF5Q47238067-02DBC07E-9D26-4E8B-8F07-A8F2CAC1DB9DQ47318847-D367E52B-5232-405A-99F9-C8C00CE03A2BQ48097821-7D4E8C3E-8F08-4630-94C4-3007A0B8F2E0Q49787333-9172F702-B50C-4B5C-9587-D9A2E4C2AF72Q50231313-F90E4584-E5DA-44B5-B70E-F709F7524C92Q52690719-00046ADA-FC0C-4333-8517-81F3CEE6493FQ53832823-BCA0D164-EADA-4102-A8A4-A9D69B174F21Q58552976-9DAB1820-EED8-41C3-9617-080A917965B7
P2860
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The BATTLE-2 Study: A Biomarke ...... ed Non-Small-Cell Lung Cancer.
@en
The BATTLE-2 Study: A Biomarke ...... ed Non-Small-Cell Lung Cancer.
@nl
type
label
The BATTLE-2 Study: A Biomarke ...... ed Non-Small-Cell Lung Cancer.
@en
The BATTLE-2 Study: A Biomarke ...... ed Non-Small-Cell Lung Cancer.
@nl
prefLabel
The BATTLE-2 Study: A Biomarke ...... ed Non-Small-Cell Lung Cancer.
@en
The BATTLE-2 Study: A Biomarke ...... ed Non-Small-Cell Lung Cancer.
@nl
P2093
P2860
P50
P356
P1476
The BATTLE-2 Study: A Biomarke ...... ed Non-Small-Cell Lung Cancer.
@en
P2093
Alda L Tam
Anne S Tsao
Caimiao Wei
David J Mauro
Don L Gibbons
Eric H Rubin
Ferdinandos Skoulidis
J Jack Lee
Ja Seok Koo
P2860
P356
10.1200/JCO.2015.66.0084
P407
P577
2016-08-01T00:00:00Z